Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary

Pfizer

Status and phase: Completed; Phase 3

Conditions: Growth Retardation; Growth Hormone Deficiency

Treatments: Drug: Somatropin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00174278

A6281217

96-8123-018

Details and patient eligibility

About

To assess the effect of long-term treatment by Genotonorm on linear growth

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All the patients who have benefit during one year of a treatment by Genotonorm during the study 94-8123-014
• All patients who have stopped during one year will be included if a signed written informed consent

Exclusion criteria

• Endocrine disease, except well substituted hypothyroidism
• Other severe chronic diseases (e.g. diabetes mellitus, cardiac or liver insufficiency)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)